Study: Surgery Generally More Cost-Effective Than Radiation for Prostate Cancer
The researchers aimed to determine the differences in outcomes and costs for various prostate cancer treatments, including radical prostatectomy (open, laparoscopic or robot-assisted) and radiation therapy (dose-escalated three-dimensional conformal RT, intensity-modulated RT, brachytherapy or combination).
The researchers used a model to determine the probable outcomes of primary treatment for hypothetical men with low-, intermediate- and high-risk localized prostate cancer. The authors based probabilities on a literature search of 232 publications and they determined costs from the USA payor perspective.
Results showed only slight differences in quality-adjusted life years across all treatment types. Surgical methods were generally more effective than RT methods, except for combined external beam and brachytherapy for high-risk disease.
However, there was a wide range of costs, spanning from $19,901 for robot-assisted prostatectomy for low-risk disease to $50,276 for combined RT for high-risk disease.
More Articles on Healthcare Cost and Quality:Study: Link Between Healthcare Cost, Quality is Unclear
6-Step Prescription for Quality Improvement in Low-Resource Areas
Patient Navigation Can Help Hospitals Reach Quality, Cost Goals
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- North America leads global infection control market with 39.5% market share: 5 takeaways
- 'Nightmare bacteria ' making its way across US facilities baffles researchers: 4 things to know
- Allergan to pay $15M fine for not disclosing 2014 merger talks in timely manner & more— 6 GI company key notes
- 10 ASC revenue cycle trends and developments to watch in 2017
- Investment alternatives to reduce portfolio risk